ExCellThera gets EMA Priority Medicines designation for ECT-001 cell therapy

Ontario Industry Updates
Written By Maura Campbell
ExCellThera.jpg

ExCellThera’s ECT-001 cell therapy for patients with blood cancers and disorders requiring stem cell transplants has received a Priority Medicines designation from the European Medicines Agency (EMA).

Maura Campbell
Previous

MCI Onehealth Closes $30 Million Initial Public Offering
Next

ManagingLife's digital solution helps manage chronic pain disability claims